{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:25:48Z","timestamp":1788859548676,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY23H160017"],"award-info":[{"award-number":["LY23H160017"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02983-z","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:54:18Z","timestamp":1760716458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Topical vaginal drug therapy in cervical cancer management: a review of clinical trials and preclinical evidence"],"prefix":"10.1007","volume":"42","author":[{"given":"Chaoqun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"6","key":"2983_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.2023.13174","volume":"330","author":"RB Perkins","year":"2023","unstructured":"Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical cancer screening a review. Jama-Journal of the American Medical Association. 2023;330(6):547\u201358. https:\/\/doi.org\/10.1001\/jama.2023.13174.","journal-title":"Jama-Journal of the American Medical Association"},{"issue":"6","key":"2983_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00109-022-02199-y","volume":"100","author":"N Khairkhah","year":"2022","unstructured":"Khairkhah N, Bolhassani A, Najafipour R. Current and future direction in treatment of HPV-related cervical disease. Journal of Molecular Medicine-Jmm. 2022;100(6):829\u201345. https:\/\/doi.org\/10.1007\/s00109-022-02199-y.","journal-title":"Journal of Molecular Medicine-Jmm"},{"issue":"12","key":"2983_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.6004\/jnccn.2023.0062","volume":"21","author":"NR Abu-Rustum","year":"2023","unstructured":"Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. Cervical Cancer, Version 12024 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2023;21(12):1225\u201333. https:\/\/doi.org\/10.6004\/jnccn.2023.0062.","journal-title":"J Natl Compr Canc Netw"},{"key":"2983_CR4","unstructured":"Bruni L AG, Serrano B, Mena M, Collado JJ, G\u00f3mez D, Mu\u00f1oz J, Bosch FX, de Sanjos\u00e9 S. Human papillomavirus and related diseases in the world. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre)2021."},{"key":"2983_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2901","author":"L Rahangdale","year":"2023","unstructured":"Rahangdale L. Human papillomavirus vaccination and cervical cancer risk. Bmj-British Medical Journal. 2023. https:\/\/doi.org\/10.1136\/bmj.p2901.","journal-title":"Bmj-British Medical Journal."},{"key":"2983_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091560","author":"C Ventura","year":"2022","unstructured":"Ventura C, Luis A, Soares CP, Venuti A, Paolini F, Pereira L, et al. The effectiveness of therapeutic vaccines for the treatment of cervical intraepithelial neoplasia 3: a systematic review and meta-analysis. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10091560.","journal-title":"Vaccines"},{"key":"2983_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-3-030-57362-1_8","volume":"217","author":"E Farmer","year":"2021","unstructured":"Farmer E, Cheng MA, Hung C-F, Wu TC. Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2021;217:157\u201395. https:\/\/doi.org\/10.1007\/978-3-030-57362-1_8.","journal-title":"Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer"},{"key":"2983_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.addr.2021.04.009","volume":"174","author":"X Wang","year":"2021","unstructured":"Wang X, Liu S, Guan Y, Ding J, Ma C, Xie Z. Vaginal drug delivery approaches for localized management of cervical cancer. Adv Drug Deliv Rev. 2021;174:114\u201326. https:\/\/doi.org\/10.1016\/j.addr.2021.04.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"2983_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3109\/02841869509127209","volume":"34","author":"J Brunet","year":"1995","unstructured":"Brunet J, Alonso C, Llanos M, Lacasta A, Fuentes J, Mendoza LA, et al. Chemotherapy and radiotherapy in locally advanced cervical-cancer. Acta Oncol. 1995;34(7):941\u20134. https:\/\/doi.org\/10.3109\/02841869509127209.","journal-title":"Acta Oncol"},{"issue":"5","key":"2983_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/s1470-2045(23)00147-x","volume":"24","author":"LR Mileshkin","year":"2023","unstructured":"Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King M, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):468\u201382. https:\/\/doi.org\/10.1016\/s1470-2045(23)00147-x.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2983_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030668","volume":"10","author":"RL Causin","year":"2021","unstructured":"Causin RL, Freitas AJAd, Trovo Hidalgo Filho CM, Reis Rd, Reis RM, Marques MMC. A systematic review of microRNAs involved in cervical cancer progression. Cells. 2021;10(3): 668.","journal-title":"Cells"},{"key":"2983_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/gels8020099","author":"R Thapa","year":"2022","unstructured":"Thapa R, Gurung S, Parat M-O, Parekh HS, Pandey P. Application of sol-gels for treatment of gynaecological conditions-physiological perspectives and emerging concepts in intravaginal drug delivery. Gels. 2022. https:\/\/doi.org\/10.3390\/gels8020099.","journal-title":"Gels"},{"key":"2983_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202303772","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Z, Feng L, Xia Y, Wei G, Lu W. Advance in nanomedicine for improving mucosal penetration and effective therapy of cervical cancer. Small. 2023. https:\/\/doi.org\/10.1002\/smll.202303772.","journal-title":"Small"},{"issue":"6","key":"2983_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s13346-017-0395-2","volume":"7","author":"I Major","year":"2017","unstructured":"Major I, McConville C. Vaginal drug delivery for the localised treatment of cervical cancer. Drug Deliv Transl Res. 2017;7(6):817\u201328. https:\/\/doi.org\/10.1007\/s13346-017-0395-2.","journal-title":"Drug Deliv Transl Res"},{"key":"2983_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100608","author":"N Desravines","year":"2020","unstructured":"Desravines N, Miele K, Carlson R, Chibwesha C, Rahangdale L. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2\u20133: a narrative review. Gynecol Oncol Rep. 2020. https:\/\/doi.org\/10.1016\/j.gore.2020.100608.","journal-title":"Gynecol Oncol Rep"},{"key":"2983_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.12.042","author":"L Rahangdale","year":"2014","unstructured":"Rahangdale L, Lippmann QK, Garcia K, Budwit D, Smith JS, van Le L. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol. 2014. https:\/\/doi.org\/10.1016\/j.ajog.2013.12.042.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2983_CR17","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1097\/01.AOG.0000438960.31355.9e","volume":"122","author":"American College of Obstetricians and Gynecologists","year":"2013","unstructured":"American College of Obstetricians and Gynecologists. Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol. 2013;122(6):1338\u201367. https:\/\/doi.org\/10.1097\/01.AOG.0000438960.31355.9e.","journal-title":"Obstet Gynecol"},{"key":"2983_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4510-7","author":"AJM van de Sande","year":"2018","unstructured":"van de Sande AJM, Koeneman MM, Gerestein CG, Kruse AJ, van Kemenade FJ, van Beekhuizen HJ. TOPical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial. BMC Cancer. 2018. https:\/\/doi.org\/10.1186\/s12885-018-4510-7.","journal-title":"BMC Cancer"},{"issue":"10337","key":"2983_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/s0140-6736(22)00624-9","volume":"399","author":"FO Voss","year":"2022","unstructured":"Voss FO, van Beurden M, Jordanova ES. Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia Comment. Lancet. 2022;399(10337):1755\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(22)00624-9.","journal-title":"Lancet"},{"issue":"1","key":"2983_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/AOG.0b013e31825bc6e8","volume":"120","author":"C Grimm","year":"2012","unstructured":"Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol. 2012;120(1):152\u20139. https:\/\/doi.org\/10.1097\/AOG.0b013e31825bc6e8.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2983_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/cji.0000000000000414","volume":"45","author":"N Hendriks","year":"2022","unstructured":"Hendriks N, Koeneman MM, van de Sande AJM, Penders CGJ, Piek JMJ, Kooreman LFS, et al. Topical imiquimod treatment of high-grade cervical intraepithelial neoplasia (TOPIC-3): a nonrandomized multicenter study. J Immunother. 2022;45(3):180\u20136. https:\/\/doi.org\/10.1097\/cji.0000000000000414.","journal-title":"J Immunother"},{"issue":"1","key":"2983_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2022.01.033","volume":"165","author":"S Polterauer","year":"2022","unstructured":"Polterauer S, Reich O, Widschwendter A, Hadjari L, Bogner G, Reinthaller A, et al. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: multicenter, randomized controlled trial. Gynecol Oncol. 2022;165(1):23\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.033.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2983_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.tjog.2012.09.006","volume":"51","author":"C-T Lin","year":"2012","unstructured":"Lin C-T, Qiu J-T, Wang C-J, Chang S-D, Tang Y-H, Wu P-J, et al. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical\/vaginal intraepithelial neoplasia. Taiwan J Obstet Gynecol. 2012;51(4):533\u20138. https:\/\/doi.org\/10.1016\/j.tjog.2012.09.006.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2983_CR24","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1016\/j.crwh.2019.e00105","volume":"21","author":"T Wouters","year":"2019","unstructured":"Wouters T, Hendriks N, Koeneman M, Kruse AJ, van de Sande A, van Beekhuizen HJ, Gerestein KG, Bekkers RL, Piek JM. Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia\u2013A case series. Case Reports in Women\u2019s Health. 2019;21:e00105. https:\/\/doi.org\/10.1016\/j.crwh.2019.e00105.","journal-title":"Case Reports in Women's Health"},{"key":"2983_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16707-5","author":"L Nerurkar","year":"2017","unstructured":"Nerurkar L, McColl A, Graham G, Cavanagh J. The systemic response to topical Aldara treatment is mediated through direct TLR7 stimulation as imiquimod enters the circulation. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/s41598-017-16707-5.","journal-title":"Sci Rep"},{"key":"2983_CR26","doi-asserted-by":"publisher","first-page":"106784","DOI":"10.1016\/j.bioorg.2023.106784","volume":"140","author":"E Mironiuk-Puchalska","year":"2023","unstructured":"Mironiuk-Puchalska E, Karatsai O, \u017buchowska A, Wr\u00f3blewski W, Borys F, Lehka L, R\u0119dowicz MJ, Koszytkowska-Stawi\u0144ska M. Development of 5-fluorouracil-dichloroacetate mutual prodrugs as anticancer agents. Bioorg Chem. 2023;140:106784. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106784.","journal-title":"Bioorg Chem"},{"issue":"6","key":"2983_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s0029-7844(99)00407-x","volume":"94","author":"M Maiman","year":"1999","unstructured":"Maiman M, Watts DH, Andersen J, Clax P, Merino M, Kendall MA. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial. Obstet Gynecol. 1999;94(6):954\u201361. https:\/\/doi.org\/10.1016\/s0029-7844(99)00407-x.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2983_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ijgo.14983","volume":"163","author":"N Desravines","year":"2023","unstructured":"Desravines N, Hsu C-H, Mohnot S, Sahasrabuddhe V, House M, Sauter E, et al. Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2\/3. Int J Gynaecol Obstet. 2023;163(3):862\u20137. https:\/\/doi.org\/10.1002\/ijgo.14983.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"2983_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/322593","volume":"33","author":"R Snoeck","year":"2001","unstructured":"Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis. 2001;33(5):597\u2013602. https:\/\/doi.org\/10.1086\/322593.","journal-title":"Clin Infect Dis"},{"issue":"2\u20133","key":"2983_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2006.06.007","volume":"71","author":"R Snoeck","year":"2006","unstructured":"Snoeck R. Papillomavirus and treatment. Antiviral Res. 2006;71(2\u20133):181\u201391. https:\/\/doi.org\/10.1016\/j.antiviral.2006.06.007.","journal-title":"Antiviral Res"},{"issue":"4","key":"2983_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1128\/cmr.16.4.569-596.2003","volume":"16","author":"E De Clercq","year":"2003","unstructured":"De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 2003;16(4):569. https:\/\/doi.org\/10.1128\/cmr.16.4.569-596.2003.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2983_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ygyno.2009.06.042","volume":"115","author":"C Van Pachterbeke","year":"2009","unstructured":"Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, et al. Topical treatment of CIN 2+by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol. 2009;115(1):69\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2009.06.042.","journal-title":"Gynecol Oncol"},{"key":"2983_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147917","author":"L Hampson","year":"2016","unstructured":"Hampson L, Maranga IO, Masinde MS, Oliver AW, Batman G, He X, et al. A single-arm, proof-of-concept trial of Lopimune (Lopinavir\/Ritonavir) as a treatment for HPV-related pre-invasive cervical disease. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0147917.","journal-title":"PLoS ONE"},{"key":"2983_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.880333","author":"L Nuranna","year":"2022","unstructured":"Nuranna L, Lubis DN, Arozal W, Purbadi S, Barinda AJ, Purwoto G, et al. Pilot study on the effect of a single topical application of trichloroacetic acid 85% on normal cervical tissue. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.880333.","journal-title":"Front Pharmacol"},{"key":"2983_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235991","author":"R Schwameis","year":"2022","unstructured":"Schwameis R, Ganhoer-Schimboeck J, Hadjari VL, Hefler L, Bergmeister B, Kuessel T, et al. TRICIN: A Phase II Trial on the Efficacy of Topical TRIchloroacetic Acid in Patients with Cervical Intraepithelial Neoplasia. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14235991.","journal-title":"Cancers (Basel)."},{"key":"2983_CR36","unstructured":"Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2015;64(3):1\u2013137."},{"issue":"1","key":"2983_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1088\/0967-3334\/24\/1\/309","volume":"24","author":"DC Walker","year":"2003","unstructured":"Walker DC, Brown BH, Blackett AD, Tidy J, Smallwood RH. A study of the morphological parameters of cervical squamous epithelium. Physiol Meas. 2003;24(1):121\u201335. https:\/\/doi.org\/10.1088\/0967-3334\/24\/1\/309.","journal-title":"Physiol Meas"},{"issue":"2","key":"2983_CR38","first-page":"227","volume":"75","author":"H Boonstra","year":"1990","unstructured":"Boonstra H, Aalders JG, Koudstaal J, Oosterhuis JW, Janssens J. Minimum extension and appropriate topographic position of tissue destruction for treatment of cervical intraepithelial neoplasia. Obstet Gynecol. 1990;75(2):227\u201331.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2983_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/aog.0000000000001244","volume":"127","author":"S Geisler","year":"2016","unstructured":"Geisler S, Speiser S, Speiser L, Heinze G, Rosenthal A, Speiser P. Short-term efficacy of trichloroacetic acid in the treatment of cervical intraepithelial neoplasia. Obstet Gynecol. 2016;127(2):353\u20139. https:\/\/doi.org\/10.1097\/aog.0000000000001244.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2983_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11532810-000000000-00000","volume":"24","author":"J-H Su","year":"2010","unstructured":"Su J-H, Wu A, Scotney E, Ma B, Monie A, Hung C-F, et al. Immunotherapy for cervical cancer research status and clinical potential. BioDrugs. 2010;24(2):109\u201329. https:\/\/doi.org\/10.2165\/11532810-000000000-00000.","journal-title":"BioDrugs"},{"issue":"21","key":"2983_CR41","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1158\/1078-0432.ccr-14-0344","volume":"20","author":"R-S Soong","year":"2014","unstructured":"Soong R-S, Song L, Trieu J, Knoff J. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFN\u03b3. Clin Cancer Res. 2014;20(21):5456\u201367. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0344.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2983_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mi.2012.83","volume":"6","author":"S Domingos-Pereira","year":"2013","unstructured":"Domingos-Pereira S, Decrausaz L, Derre L, Bobst M, Romero P, Schiller JT, et al. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol. 2013;6(2):393\u2013404. https:\/\/doi.org\/10.1038\/mi.2012.83.","journal-title":"Mucosal Immunol"},{"key":"2983_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0593-1","author":"S Domingos-Pereira","year":"2019","unstructured":"Domingos-Pereira S, Galliverti G, Hanahan D, Nardelli-Haefliger D. Carboplatin\/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors. J Immunother Cancer. 2019. https:\/\/doi.org\/10.1186\/s40425-019-0593-1.","journal-title":"J Immunother Cancer"},{"key":"2983_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081733","author":"C-PH Yang","year":"2017","unstructured":"Yang C-PH, Horwitz SB. Taxol\u00ae: the first microtubule stabilizing agent. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18081733.","journal-title":"Int J Mol Sci"},{"key":"2983_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201903208","author":"Q Qian","year":"2019","unstructured":"Qian Q, Shi L, Gao X, Ma Y. A paclitaxel-based mucoadhesive nanogel with multivalent interactions for cervical cancer therapy. Small. 2019. https:\/\/doi.org\/10.1002\/smll.201903208.","journal-title":"Small"},{"issue":"7","key":"2983_CR46","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/adhm.201300519","volume":"3","author":"M Yang","year":"2014","unstructured":"Yang M, Yu T, Wang Y-Y, Lai SK, Zeng Q, Miao B, et al. Vaginal delivery of Paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater. 2014;3(7):1044\u201352. https:\/\/doi.org\/10.1002\/adhm.201300519.","journal-title":"Adv Healthc Mater"},{"key":"2983_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep20051","author":"MS Zaman","year":"2016","unstructured":"Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, et al. Curcumin nanoformulation for cervical cancer treatment. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep20051.","journal-title":"Sci Rep"},{"key":"2983_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejpb.2015.03.029","volume":"93","author":"S Zong","year":"2015","unstructured":"Zong S, Wang X, Yang Y, Wu W, Li H, Ma Y, et al. The use of cisplatin-loaded mucoadhesive nanofibers for local chemotherapy of cervical cancers in mice. Eur J Pharm Biopharm. 2015;93:127\u201335. https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.029.","journal-title":"Eur J Pharm Biopharm"},{"key":"2983_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jconrel.2021.07.008","volume":"336","author":"F Lv","year":"2021","unstructured":"Lv F, Wang J, Chen H, Sui L, Feng L, Liu Z, et al. Enhanced mucosal penetration and efficient inhibition efficacy against cervical cancer of PEGylated docetaxel nanocrystals by TAT modification. J Control Release. 2021;336:572\u201382. https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.008.","journal-title":"J Control Release"},{"issue":"1","key":"2983_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0924-8579(99)00004-7","volume":"12","author":"G Gross","year":"1999","unstructured":"Gross G. Do we need antivirals for genital herpes simplex virus and human papillomavirus infection? Int J Antimicrob Agents. 1999;12(1):1\u20133. https:\/\/doi.org\/10.1016\/s0924-8579(99)00004-7.","journal-title":"Int J Antimicrob Agents"},{"issue":"1\u20132","key":"2983_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0378-5173(02)00178-3","volume":"242","author":"S Santoyo","year":"2002","unstructured":"Santoyo S, de Jal\u00f3n EG, Ygartua P, Renedo MJ, Blanco-Pr\u00edeto MJ. Optimization of topical cidofovir penetration using microparticles. Int J Pharm. 2002;242(1\u20132):107\u201313. https:\/\/doi.org\/10.1016\/s0378-5173(02)00178-3.","journal-title":"Int J Pharm"},{"issue":"17","key":"2983_CR52","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/09205063.2015.1082808","volume":"26","author":"F Tugcu-Demiroz","year":"2015","unstructured":"Tugcu-Demiroz F, Acarturk F, Ozkul A. Preparation and characterization of bioadhesive controlled-release gels of cidofovir for vaginal delivery. J Biomater Sci-Polym Ed. 2015;26(17):1237\u201355. https:\/\/doi.org\/10.1080\/09205063.2015.1082808.","journal-title":"J Biomater Sci-Polym Ed"},{"issue":"2","key":"2983_CR53","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ijpharm.2017.04.036","volume":"531","author":"C Varan","year":"2017","unstructured":"Varan C, Wickstrom H, Sandler N, Aktas Y, Bilensoy E. Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration. Int J Pharm. 2017;531(2):701\u201313. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.04.036.","journal-title":"Int J Pharm"},{"issue":"2","key":"2983_CR54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2004.02.004","volume":"209","author":"DP O'Neal","year":"2004","unstructured":"O\u2019Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004;209(2):171\u20136. https:\/\/doi.org\/10.1016\/j.canlet.2004.02.004.","journal-title":"Cancer Lett"},{"issue":"2","key":"2983_CR55","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1021\/acsami.7b15332","volume":"10","author":"Y-W Bao","year":"2018","unstructured":"Bao Y-W, Hua X-W, Li Y-H, Jia H-R, Wu F-G. Hyperthemia-promoted cytosolic and nuclear delivery of copper\/carbon quantum dot-crosslinked nanosheets: multimodal imaging-guided photothermal cancer therapy. ACS Appl Mater Interfaces. 2018;10(2):1544\u201355. https:\/\/doi.org\/10.1021\/acsami.7b15332.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"17","key":"2983_CR56","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1021\/ja2010175","volume":"133","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, Tabakman SM, Liang Y, Wang H, Casalongue HS, Daniel V, et al. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J Am Chem Soc. 2011;133(17):6825\u201331. https:\/\/doi.org\/10.1021\/ja2010175.","journal-title":"J Am Chem Soc"},{"issue":"4","key":"2983_CR57","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1021\/acsami.7b16222","volume":"10","author":"G Zhao","year":"2018","unstructured":"Zhao G, Wu H, Feng R, Wang D, Xu P, Jiang P, et al. Novel metal polyphenol framework for MR imaging-guided photothermal therapy. ACS Appl Mater Interfaces. 2018;10(4):3295\u2013304. https:\/\/doi.org\/10.1021\/acsami.7b16222.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"2983_CR58","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/anie.201710399","volume":"57","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Chang Y, Feng Y, Jian H, Tang Z, Zhang H. Deep-level defect enhanced photothermal performance of bismuth sulfide-gold heterojunction nanorods for photothermal therapy of cancer guided by computed tomography imaging. Angewandte Chemie-International Edition. 2018;57(1):246\u201351. https:\/\/doi.org\/10.1002\/anie.201710399.","journal-title":"Angewandte Chemie-International Edition"},{"issue":"3","key":"2983_CR59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1039\/c8mh00966j","volume":"6","author":"KD Patel","year":"2019","unstructured":"Patel KD, Singh RK, Kim H-W. Carbon-based nanomaterials as an emerging platform for theranostics. Mater Horiz. 2019;6(3):434\u201369. https:\/\/doi.org\/10.1039\/c8mh00966j.","journal-title":"Mater Horiz"},{"key":"2983_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2020.127710","author":"X Cui","year":"2021","unstructured":"Cui X, Li M, Wei F, Tang X, Xu W, Li M, et al. Biomimetic light-activatable graphene-based nanoarchitecture for synergistic chemophotothermal therapy. Chem Eng J. 2021. https:\/\/doi.org\/10.1016\/j.cej.2020.127710.","journal-title":"Chem Eng J"},{"issue":"7","key":"2983_CR61","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.7150\/thno.14431","volume":"6","author":"Z Dong","year":"2016","unstructured":"Dong Z, Gong H, Gao M, Zhu W, Sun X, Feng L, et al. Polydopamine nanoparticles as a versatile molecular loading platform to enable imaging-guided cancer combination therapy. Theranostics. 2016;6(7):1031\u201342. https:\/\/doi.org\/10.7150\/thno.14431.","journal-title":"Theranostics"},{"issue":"3","key":"2983_CR62","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1021\/nn400334y","volume":"7","author":"M Zheng","year":"2013","unstructured":"Zheng M, Yue C, Ma Y, Gong P, Zhao P, Zheng C, et al. Single-step assembly of DOX\/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano. 2013;7(3):2056\u201367. https:\/\/doi.org\/10.1021\/nn400334y.","journal-title":"ACS Nano"},{"issue":"9","key":"2983_CR63","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1039\/c9bm00756c","volume":"7","author":"X Wang","year":"2019","unstructured":"Wang X, Wang L, Zong S. Use of multifunctional composite nanofibers for photothermalchemotherapy to treat cervical cancer in mice. Biomater Sci. 2019;7(9):3846\u201354. https:\/\/doi.org\/10.1039\/c9bm00756c.","journal-title":"Biomater Sci"},{"issue":"5","key":"2983_CR64","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/jcm11051432","volume":"11","author":"CL Muntinga","year":"2022","unstructured":"Muntinga CL, de vos van Steenwijk PJ, Bekkers RL, van Esch EM. Importance of the immune microenvironment in the spontaneous regression of cervical squamous intraepithelial lesions (cSIL) and implications for immunotherapy. J Clin Med. 2022;11(5):1432. https:\/\/doi.org\/10.3390\/jcm11051432.","journal-title":"J Clin Med"},{"issue":"2","key":"2983_CR65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","volume":"61","author":"SK Lai","year":"2009","unstructured":"Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158\u201371. https:\/\/doi.org\/10.1016\/j.addr.2008.11.002.","journal-title":"Adv Drug Deliv Rev"},{"key":"2983_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2017.11.001","volume":"124","author":"JY Lock","year":"2018","unstructured":"Lock JY, Carlson TL, Carrier RL. Mucus models to evaluate the diffusion of drugs and particles. Adv Drug Deliv Rev. 2018;124:34\u201349. https:\/\/doi.org\/10.1016\/j.addr.2017.11.001.","journal-title":"Adv Drug Deliv Rev"},{"key":"2983_CR67","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1749-6632.1997.tb48550.x","volume":"828","author":"D De Ziegler","year":"1997","unstructured":"De Ziegler D, Bulletti C, De Monstier B, Jaaskelainen AS. The first uterine pass effect. Ann N Y Acad Sci. 1997;828:291\u20139. https:\/\/doi.org\/10.1111\/j.1749-6632.1997.tb48550.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2983_CR68","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/humrep\/12.5.1073","volume":"12","author":"C Bulletti","year":"1997","unstructured":"Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12(5):1073\u20139. https:\/\/doi.org\/10.1093\/humrep\/12.5.1073.","journal-title":"Hum Reprod"},{"key":"2983_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106945","author":"Y Xin","year":"2025","unstructured":"Xin Y, Fei W, Zhang M, Chen Y, Peng Y, Sun D, et al. Uterine first-pass effect: unlocking the potential of vaginally administered ritodrine-loaded thermosensitive gel for uterine drug delivery. Eur J Pharm Sci. 2025. https:\/\/doi.org\/10.1016\/j.ejps.2024.106945.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"2983_CR70","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/15384047.2018.1470722","volume":"19","author":"R Yamaguchi","year":"2018","unstructured":"Yamaguchi R, Perkins G. Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. Cancer Biol Ther. 2018;19(9):745\u201354. https:\/\/doi.org\/10.1080\/15384047.2018.1470722.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"2983_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1053\/j.seminoncol.2014.02.004","volume":"41","author":"D Lindner","year":"2014","unstructured":"Lindner D. Animal models and the tumor microenvironment: studies of tumor-host symbiosis. Semin Oncol. 2014;41(2):146\u201355. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.02.004.","journal-title":"Semin Oncol"},{"key":"2983_CR72","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gde.2013.11.008","volume":"24","author":"S Budhu","year":"2014","unstructured":"Budhu S, Wolchok J, Merghoub T. The importance of animal models in tumor immunity and immunotherapy. Curr Opin Genet Dev. 2014;24:46\u201351. https:\/\/doi.org\/10.1016\/j.gde.2013.11.008.","journal-title":"Curr Opin Genet Dev"},{"issue":"6","key":"2983_CR73","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/aog.0000000000004384","volume":"137","author":"BO Fonseca","year":"2021","unstructured":"Fonseca BO, Possati-Resende JC, Salcedo MP, Schmeler KM, Accorsi GS, Fregnani JHTG, et al. Topical imiquimod for the treatment of high-grade squamous intraepithelial lesions of the cervix a randomized controlled trial. Obstet Gynecol. 2021;137(6):1043\u201353. https:\/\/doi.org\/10.1097\/aog.0000000000004384.","journal-title":"Obstet Gynecol"},{"key":"2983_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.06.105","author":"DR Pachman","year":"2012","unstructured":"Pachman DR, Barton DL, Clayton AC, McGovern RM, Jefferies JA, Novotny PJ, et al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol. 2012. https:\/\/doi.org\/10.1016\/j.ajog.2011.06.105.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02983-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02983-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02983-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:33:47Z","timestamp":1762425227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02983-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2983"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02983-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"523"}}